Valuation: Corbus Pharmaceuticals Holdings, Inc.

Market Cap 207M 177M 166M 152M 286M 19.71B 289M 1.96B 762M 9.94B 776M 759M 32.93B P/E 2026 *
-1.95x
P/E 2027 * -1.86x
Enterprise Value 207M 177M 166M 152M 286M 19.71B 289M 1.96B 762M 9.94B 776M 759M 32.93B EV / Sales 2026 *
186x
EV / Sales 2027 * 86.1x
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Corbus Pharmaceuticals Holdings, Inc.

1 day+5.80%
1 week+7.82%
Current month+26.09%
1 month+23.34%
3 months-0.35%
6 months+48.23%
Current year+38.94%
1 week 9.68
Extreme 9.68
11.35
1 month 8.62
Extreme 8.615
11.35
Current year 7.12
Extreme 7.12
12.88
1 year 7.12
Extreme 7.12
20.56
3 years 3.03
Extreme 3.0334
61.9
5 years 2.11
Extreme 2.11
61.9
10 years 2.11
Extreme 2.11
323.4
Manager TitleAgeSince
Chief Executive Officer 51 11/04/2014
Director of Finance/CFO 68 11/04/2014
Chief Tech/Sci/R&D Officer 48 06/07/2026
Director TitleAgeSince
Director/Board Member 51 11/04/2014
Director/Board Member 68 05/06/2018
Chairman 54 15/05/2025
Date Insider Type Main position Quantity % Market Cap.
8/16/26 A Free

Chief Technology Officer

250,009 1.3494%
8/11/26 A Buy

Executive/Senior Manager

2,600 0.0140%
8/7/26 A Sell

Chief Financial Officer

-12,000 0.0648%
Change 5-day change 1-year change 3-year change Capi.($)
+5.80%+7.82%+15.53%+73.73% 207M
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+24.51%+2.86%-4.20% 28.34B
-0.07%-3.45%-6.06%+464.93% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+8.41%+46.83%+160.78% 13.52B
Average +2.97%+3.74%+57.05%+186.12% 28.15B
Weighted average by Cap. +2.64%+2.95%+59.31%+157.91%

Financials

2026 *2027 *
Net sales 1.11M 952K 892K 815K 1.54M 106M 1.55M 10.52M 4.1M 53.44M 4.17M 4.08M 177M 2.4M 2.06M 1.93M 1.76M 3.32M 229M 3.35M 22.73M 8.85M 115M 9.01M 8.82M 382M
Net income -116M -99.63M -93.36M -85.27M -161M -11.08B -163M -1.1B -429M -5.59B -437M -427M -18.52B -135M -116M -109M -99.12M -187M -12.88B -189M -1.28B -498M -6.5B -507M -496M -21.53B
Net Debt - -
Logo Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Employees
36
Date Price Change Volume
25/08/26 $11.31 +5.80% 1,279,817
24/08/26 $10.69 +2.99% 1,313,673
21/08/26 $10.38 +5.49% 604,017
20/08/26 $9.840 -1.50% 300,397
19/08/26 $9.990 -0.89% 345,728
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.69USD
Average target price
34.52USD
Spread / Average Target
+222.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRBP Stock